Abstract P2-08-04: Progressive metastatic breast cancer with no detectable circulating tumor DNA: Evaluating limitations of this highly sensitive tool

Ami N. Shah(Northwestern University), Massimo Cristofanilli(Cornell University), Andrew A. Davis(Northwestern University), Michael Gurley(Northwestern University), Firas Wehbe(Northwestern University), Millen Srivastava(Northwestern University), Anthony K. Kang(Northwestern University), Lorenzo Gerratana(National Cancer Institute), Paolo D’Amico(Ripamonti), Carolina Reduzzi(Cornell University), Amir Behdad(Beth Israel Deaconess Medical Center), Saya Jacob(University of Pennsylvania), William J. Gradishar(Northwestern University), Neelima Katam(Northwestern University), Dhruvika Mukhija(Northwestern University), Qiang Zhang(Northwestern University), Shruti Chandra(Northwestern University)
Cancer Research
February 15, 2022
10.1158/1538-7445.sabcs21-p2-08-04
Cited by 0

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k